Skip to main content

The Cyclone® KIUBE custom energy was successfully rigged at the Prince of Songkla University (PSU).

cyclotron at the Prince of Songkla University (PSU).

Friday, April 30, 2021 - 11:15

<p>The cyclotron was placed into its final position at the PSU ! The project offered jointly by Philips and IBA includes the integration of the cyclotron, the cameras, all necessary lab equipment,… as well as the facility layout and design for the establishment of a cutting edge GMP radiopharmaceutical production centers. The new PET center will produce various molecules including FDG and Ga-PSMA on the Synthera®+ platform but also N-13, C-11 and O-15 compounds!</p>

More news

eSRS symposium

Register for the eSRS Satellite Symposium : From new tracers developments to routine clinical applications on Synthera® + platform

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To be able to cover the growing clinical demands, radiopharmacies are developing new tracers while keeping up their routine production in a (c)GMP environment.&nbsp; In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD.will share their experience in the development of new tracers on the Synthera® Platform.&nbsp; When? &nbsp;May 20th 4-5pm CET (Central European Time) &nbsp; REGISTER What will you learn ? &nbsp; Synthesis of [18F]mFBG and [18F]FE-PE2I on Synthera®+ platform By Dr. Ida Nymann Petersen, PhD., Radiochemist at Rigshospitalet in Copenhagen, Denmark. &nbsp; In this talk, the fully automated labelling of [18F]mFBG and [18F]FE-PE2I on the Synthera®+ and Synthera®+ HPLC platform will be presented. [18F]FE-PE2I was synthesized in 32 % RCY, 98 % RCP in 40 min. [18F]mFBG is currently under optimization.&nbsp; &nbsp; Development of new tracers: from neurology to oncology applications. By Dr. Vasko Kramer, PhD., Head of Research &amp; Development at Positron Pharma in Santiago, Chile.&nbsp; He will present some of their results for the production and development of new, innovative PET imaging agents for neurological ([18F]F-PR04.MZ, [18F]F-Florbetaben, [18F]F-PI-2620), oncological ([18F]FAPi-74, [18F]F-AlF-NOTA-Octreotide), and research applications (7-[18F]F-Fluoro-tryptophan, 18F-Tetrazines) using a compact, cassette-based synthesis platform. &nbsp; &nbsp; You can join this symposium even if you don’t attend eSRS meeting.
See more